Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Study Overview
=================
Brief Summary
-----------------
The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180. We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

Official Title
-----------------
Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study

Conditions
-----------------
Glioma

Intervention / Treatment
-----------------
* Drug: [18F]DPA-714


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age greater than or equal to 18 years Suspicion of an operable diffuse glioma Written informed consent (signed) Affiliated or beneficiary of a social security plan Exclusion Criteria: Suspicion of grade I glioma Surgical urgency (less than 8 days between the suspected diagnosis and surgery) Pregnant or breastfeeding woman Persons deprived of liberty or under guardianship Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: [18F]DPA-714 PET<br> | Drug: [18F]DPA-714<br>* Participant received one injection of 200 MBq of [18F]DPA-714<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic performances of [18F]DPA-714 PET for glioma grading obtained by stereotactic biopsies of glioma | Sensitivity and specificity of [18F]DPA-714 PET using anatomopathological assessment of biopsies as gold standard | [18F]DPA-714 PET performed up to 30 days before brain surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of [18F]DPA-714 PET quantitative parameters with anatomopathological assessment of the surgery specimen | Comparison of [18F]DPA-714 PET quantitative parameters with the histological types of gliomas, with the IDH1-mutational status, and the 1p19q codeletion status | [18F]DPA-714 PET performed up to 30 days before brain surgery | 
| Comparison of [18F]DPA-714 PET quantitative parameters with tumor microenvironment | Comparison of [18F]DPA-714 PET quantitative parameters with the frequency and phenotype of tumor microenvironment different glioma-associated cells | [18F]DPA-714 PET performed up to 30 days before brain surgery |